MX2009003410A - Fosfoindoles enantiomericamente puros como inhibidores de vih. - Google Patents
Fosfoindoles enantiomericamente puros como inhibidores de vih.Info
- Publication number
- MX2009003410A MX2009003410A MX2009003410A MX2009003410A MX2009003410A MX 2009003410 A MX2009003410 A MX 2009003410A MX 2009003410 A MX2009003410 A MX 2009003410A MX 2009003410 A MX2009003410 A MX 2009003410A MX 2009003410 A MX2009003410 A MX 2009003410A
- Authority
- MX
- Mexico
- Prior art keywords
- hydrogen
- nrr
- heterocyclyl
- alkynyl
- alkenyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003006 phosphoindoles Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- KJDLQEJTNPEOLU-UHFFFAOYSA-N C1=CC=C2C(P(=O)=O)=CNC2=C1 Chemical class C1=CC=C2C(P(=O)=O)=CNC2=C1 KJDLQEJTNPEOLU-UHFFFAOYSA-N 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- -1 arnido Chemical group 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos de 3-fosfoindol sustancialmente en la forma de un solo enantiómero útil para el tratamiento de infecciones por virus Flaviviridae, y particularmente para infecciones por VIH. También se proporcionan composiciones farmacéuticas que comprenden los compuestos de 3-fosfoindol solos o en combinación con uno o más agentes antivirales diferentes, procesos para su preparación, y métodos para la fabricación de un medicamento que incorpora estos compuestos. Los compuestos de 3-fosfoindol son de la fórmula (A) o (B): (ver fórmulas (A y B)) y las sales farmacéuticamente aceptables, solvatos, hidratos, o ésteres de los mismos. En las fórmulas, X es hidrógeno, arilo o heterociclilo; alquenilo de 2 a 6 átomos de carbono, alquinilo de 2 a 6 átomos de carbono, o alquilo; Y es hidrógeno, -R, -O-R, -NH-R, o -NRR; Z es -OR, -NHR, -NRR, carboxamido, amido, carboxilo, carbonilo, o un residuo de aminoácido; R1 es hidrógeno, acilo, -S(O)n-R, carboxilo, carbonilo, o un residuo de aminoácido; cada R4'; R5', R6' y R7' es independientemente hidrógeno, alquenilo de 2 a 6 átomos de carbono, alquinilo de 2 a 6 átomos de carbono, arilo, heterociclilo, halógeno, -CN, CF3, -OR, -NHR, -NRR, o-NO2; n es 0, 1, ó 2; y cada R es independientemente hidrógeno, alquilo., alquenilo de 2 a 6 átomos de carbono, alquinilo de 2 a 6 átomos de carbono, arilo, o heterociclilo. (ver figura (1B)).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84858406P | 2006-09-29 | 2006-09-29 | |
| US85798006P | 2006-11-09 | 2006-11-09 | |
| US90311507P | 2007-02-23 | 2007-02-23 | |
| PCT/US2007/020900 WO2008042240A2 (en) | 2006-09-29 | 2007-09-28 | Enantiomerically pure phosphoindoles as hiv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003410A true MX2009003410A (es) | 2009-07-17 |
Family
ID=39145445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003410A MX2009003410A (es) | 2006-09-29 | 2007-09-28 | Fosfoindoles enantiomericamente puros como inhibidores de vih. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7960428B2 (es) |
| EP (1) | EP2078029B1 (es) |
| JP (1) | JP2010504978A (es) |
| KR (1) | KR20090077813A (es) |
| AU (1) | AU2007305447A1 (es) |
| BR (1) | BRPI0717511A2 (es) |
| CA (1) | CA2664396A1 (es) |
| CO (1) | CO6190525A2 (es) |
| CR (1) | CR10693A (es) |
| EA (1) | EA016267B1 (es) |
| ES (1) | ES2488922T3 (es) |
| IL (1) | IL197777A (es) |
| MA (1) | MA30806B1 (es) |
| MX (1) | MX2009003410A (es) |
| NO (1) | NO20091258L (es) |
| NZ (1) | NZ575831A (es) |
| TW (1) | TW200821287A (es) |
| WO (1) | WO2008042240A2 (es) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005011031D1 (en) * | 2004-09-17 | 2008-12-24 | Idenix Pharmaceuticals Inc | Phosphoindole als hiv-inhibitoren |
| ES2488922T3 (es) | 2006-09-29 | 2014-09-01 | Idenix Pharmaceuticals, Inc. | Fosfoindoles enantiómeramente puros como inhibidores del HIV |
| TWI384986B (zh) * | 2007-01-17 | 2013-02-11 | Lg Life Sciences Ltd | 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物 |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| TW200944537A (en) * | 2008-04-03 | 2009-11-01 | Idenix Pharmaceuticals Inc | Formulations comprising a phosphoindole compound and one or more second active agents |
| CN102115452A (zh) * | 2009-12-30 | 2011-07-06 | 上海特化医药科技有限公司 | (e)-3-(3-取代-5-甲基苯基)丙烯腈及其制备方法 |
| LT3494972T (lt) | 2010-01-27 | 2024-03-12 | Viiv Healthcare Company | Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti |
| KR101301253B1 (ko) * | 2011-12-09 | 2013-08-28 | 한국원자력연구원 | 방사선을 이용한 크로메논 유도체의 제조방법 |
| US10081592B2 (en) | 2012-03-23 | 2018-09-25 | The Board Of Trustees Of The University Of Illinois | Complex and structurally diverse compounds |
| US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9867819B2 (en) | 2013-11-05 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9968568B2 (en) | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200261431A1 (en) | 2019-01-07 | 2020-08-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9861595B2 (en) | 2013-11-05 | 2018-01-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9700528B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9457025B2 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US9474731B1 (en) | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9707191B2 (en) | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
| US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9457023B1 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20160324807A1 (en) | 2013-11-05 | 2016-11-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20160361305A1 (en) | 2013-11-05 | 2016-12-15 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9683220B2 (en) | 2015-07-07 | 2017-06-20 | Codexis, Inc. | P450-BM3 variants with improved activity |
| CN111404764B (zh) * | 2019-01-02 | 2021-11-19 | 中国移动通信有限公司研究院 | 一种电信云预集成部署测试方法及装置 |
| US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| WO2022066978A1 (en) * | 2020-09-24 | 2022-03-31 | Lee Chien Chang | Prophylatic use of calcium channel blockers in tuberculosis |
| JP2024503989A (ja) | 2021-01-11 | 2024-01-30 | アルコン インコーポレイティド | 粘弾性体送達のためのシステム及び方法 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4866084A (en) * | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
| US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| US5124327A (en) | 1991-09-06 | 1992-06-23 | Merck & Co., Inc. | HIV reverse transcriptase |
| DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| WO1994019321A1 (en) * | 1993-02-24 | 1994-09-01 | Merck & Co., Inc. | Inhibitors of hiv reverse transcriptase |
| US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
| US5612330A (en) * | 1994-03-07 | 1997-03-18 | Warner-Lambert Company | Methods for inhibiting and controlling viral growth |
| US5489586A (en) * | 1994-03-07 | 1996-02-06 | Warner-Lambert Company | Method for treating inflammatory disease in humans |
| US5489685A (en) | 1994-05-12 | 1996-02-06 | Merck & Co., Ltd. | Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters |
| DE69525418T2 (de) * | 1994-05-31 | 2002-10-17 | Mitsui Chemicals, Inc. | Benzimidazol-derivate |
| US5734081A (en) * | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| HUP9901096A3 (en) * | 1995-01-10 | 2000-12-28 | Smithkline Beecham Spa | Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| FR2748207B1 (fr) * | 1996-05-06 | 1998-06-12 | Cird Galderma | Composition a base d'un compose modulant la reactivite des fibres nerveuses |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| GB9614347D0 (en) | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
| KR20000036227A (ko) | 1996-09-27 | 2000-06-26 | 토마스 씨. 서 | 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법 |
| US5759842A (en) | 1996-10-24 | 1998-06-02 | Merck & Co., Inc. | In vitro HIV integrase inhibitors |
| US5939414A (en) | 1996-10-31 | 1999-08-17 | Merck & Co., Inc. | Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase |
| US5858738A (en) | 1996-11-07 | 1999-01-12 | Merck & Co., Inc. | Ermophilane sesquiterpenoids as HIV intergrase inhibitors |
| US5830894A (en) * | 1997-02-21 | 1998-11-03 | Viropharma Incorporated | Methods for preventing and treating pestivirus infection and associated diseases |
| US6068988A (en) | 1997-02-28 | 2000-05-30 | Biosynth Ag | Detection of microbial metabolites with a 3-indoxyl-myo-inositol-1-phosphate compound |
| US5935982A (en) * | 1997-02-28 | 1999-08-10 | The University Of North Carolina At Chapel Hill | Methods of treating retroviral infection and compounds useful therefor |
| WO1998053812A1 (en) | 1997-05-27 | 1998-12-03 | Guilford Pharmaceuticals Inc. | Inhibitors of naaladase enzyme activity |
| US6124327A (en) | 1997-07-29 | 2000-09-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6403347B1 (en) | 1998-02-03 | 2002-06-11 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6110716A (en) | 1998-02-04 | 2000-08-29 | Merck & Co., Inc. | HIV integrase inhibitors |
| KR20010041705A (ko) * | 1998-03-26 | 2001-05-25 | 시오노 요시히코 | 항바이러스성 활성을 가진 인돌 유도체 |
| IT1299068B1 (it) | 1998-04-10 | 2000-02-07 | Chemi Spa | Legandi fosforati chirali e loro complessi organometallici, utili come catalizzatori in sintesi stereoselettive |
| US6380249B1 (en) | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6262055B1 (en) | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6306891B1 (en) | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
| DE19853558A1 (de) | 1998-11-20 | 2000-05-31 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von 2,3-Dihydroindolen (Indolinen), neuartige 2,3-Dihydroindole sowie deren Verwendung |
| WO2000036132A1 (en) | 1998-12-14 | 2000-06-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
| GB9914371D0 (en) | 1999-06-18 | 1999-08-18 | Smithkline Beecham Plc | Novel compounds |
| US6245806B1 (en) | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
| AU8009900A (en) | 1999-10-13 | 2001-04-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
| AU763356C (en) | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6541515B2 (en) | 2000-08-09 | 2003-04-01 | Merck & Co., Inc. | HIV integrase inhibitors |
| DE60124577T2 (de) | 2000-10-12 | 2007-09-27 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| ATE364385T1 (de) | 2000-10-12 | 2007-07-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| SK4322003A3 (en) | 2000-10-12 | 2003-09-11 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors |
| ATE451921T1 (de) | 2001-04-11 | 2010-01-15 | Idenix Cayman Ltd | Phenylindole zur behandlung von hiv |
| US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| US20030236277A1 (en) * | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
| CN101074242A (zh) | 2002-04-26 | 2007-11-21 | 吉里德科学公司 | Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物 |
| US6900206B2 (en) * | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
| US20040063746A1 (en) | 2002-07-25 | 2004-04-01 | Alicia Regueiro-Ren | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives |
| JP2006500355A (ja) | 2002-08-07 | 2006-01-05 | イデニクス（ケイマン）リミテツド | Ｈｉｖ治療用の置換フェニルインドール類 |
| SI1564210T1 (sl) | 2002-11-20 | 2010-01-29 | Japan Tobacco Inc | 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze |
| DE602005011031D1 (en) | 2004-09-17 | 2008-12-24 | Idenix Pharmaceuticals Inc | Phosphoindole als hiv-inhibitoren |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| ES2488922T3 (es) * | 2006-09-29 | 2014-09-01 | Idenix Pharmaceuticals, Inc. | Fosfoindoles enantiómeramente puros como inhibidores del HIV |
-
2007
- 2007-09-28 ES ES07838974.9T patent/ES2488922T3/es active Active
- 2007-09-28 KR KR1020097008921A patent/KR20090077813A/ko not_active Ceased
- 2007-09-28 NZ NZ575831A patent/NZ575831A/en not_active IP Right Cessation
- 2007-09-28 MX MX2009003410A patent/MX2009003410A/es active IP Right Grant
- 2007-09-28 JP JP2009530421A patent/JP2010504978A/ja active Pending
- 2007-09-28 EP EP07838974.9A patent/EP2078029B1/en active Active
- 2007-09-28 AU AU2007305447A patent/AU2007305447A1/en not_active Abandoned
- 2007-09-28 CA CA002664396A patent/CA2664396A1/en not_active Abandoned
- 2007-09-28 EA EA200900358A patent/EA016267B1/ru not_active IP Right Cessation
- 2007-09-28 US US11/906,095 patent/US7960428B2/en not_active Expired - Fee Related
- 2007-09-28 WO PCT/US2007/020900 patent/WO2008042240A2/en not_active Ceased
- 2007-09-28 BR BRPI0717511-6A patent/BRPI0717511A2/pt not_active IP Right Cessation
- 2007-09-29 TW TW096136663A patent/TW200821287A/zh unknown
-
2009
- 2009-03-24 IL IL197777A patent/IL197777A/en not_active IP Right Cessation
- 2009-03-26 CR CR10693A patent/CR10693A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091258A patent/NO20091258L/no not_active Application Discontinuation
- 2009-03-31 CO CO09033082A patent/CO6190525A2/es not_active Application Discontinuation
- 2009-04-22 MA MA31808A patent/MA30806B1/fr unknown
-
2011
- 2011-06-02 US US13/152,018 patent/US8486991B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2078029B1 (en) | 2014-05-14 |
| TW200821287A (en) | 2008-05-16 |
| US7960428B2 (en) | 2011-06-14 |
| ES2488922T3 (es) | 2014-09-01 |
| WO2008042240A2 (en) | 2008-04-10 |
| EP2078029A2 (en) | 2009-07-15 |
| IL197777A (en) | 2013-08-29 |
| JP2010504978A (ja) | 2010-02-18 |
| CR10693A (es) | 2009-06-25 |
| NZ575831A (en) | 2011-12-22 |
| AU2007305447A1 (en) | 2008-04-10 |
| MA30806B1 (fr) | 2009-10-01 |
| CO6190525A2 (es) | 2010-08-19 |
| WO2008042240A3 (en) | 2008-06-05 |
| HK1129679A1 (en) | 2009-12-04 |
| NO20091258L (no) | 2009-06-22 |
| US20080213217A1 (en) | 2008-09-04 |
| WO2008042240A9 (en) | 2008-08-07 |
| EA016267B1 (ru) | 2012-03-30 |
| CA2664396A1 (en) | 2008-04-10 |
| IL197777A0 (en) | 2009-12-24 |
| BRPI0717511A2 (pt) | 2013-11-19 |
| EA200900358A1 (ru) | 2009-10-30 |
| US20110257129A1 (en) | 2011-10-20 |
| US8486991B2 (en) | 2013-07-16 |
| KR20090077813A (ko) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| GEP20156368B (en) | Non-nucleoside reverse transcriptase inhibitors | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| NZ600816A (en) | Inhibitors of flaviviridae viruses | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
| GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
| MX2009009920A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| AR077765A1 (es) | Inhibidores de los virus flaviviridae | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| WO2010068760A3 (en) | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | |
| GEP201606545B (en) | 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections | |
| EA201170537A1 (ru) | Ингибиторы вич-интегразы | |
| UA98775C2 (ru) | Энантиомерно чистые фосфоиндолы как ингибиторы вич | |
| AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
| MX2009010932A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| GEP20115240B (en) | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ATE517899T1 (de) | Hiv-integrasehemmer | |
| TW200728291A (en) | Amide derivatives | |
| ATE473212T1 (de) | Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine | |
| AR057651A1 (es) | Derivados n-amida de 8-azabiciclo[3.2.1]oct-3-ilo como antagonistas de ccr1, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas | |
| AR073964A1 (es) | Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |